HR+/HER2- Breast Cancer Clinical Trials in Hangzhou
2 recruitingHangzhou, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University30 enrolled11 locationsNCT06611813
Recruiting
Phase 3
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University194 enrolled13 locationsNCT06977893